New hope for stubborn high blood pressure? phase 3 trial launches
NCT ID NCT07635914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests aprocitentan, a drug already approved in some countries, for people with resistant hypertension—high blood pressure that stays high despite taking three or more medications. About 382 adults will receive either the drug or a placebo for 8 weeks. The main goal is to see if aprocitentan can safely lower sitting systolic blood pressure more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aprocitentan tablets
What this could lead to
If it works, this could offer a new treatment option for people whose blood pressure remains high despite taking multiple medications.
What could go wrong
This is a Phase 3 trial, but it is not yet recruiting. The drug may not lower blood pressure significantly more than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESISTANT HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••